Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
-
Publication number: 20140287037Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).Type: ApplicationFiled: January 17, 2014Publication date: September 25, 2014Applicant: UPSHER-SMITH LABORATORIES, INC.Inventors: Sarah Michelle Betterman, Jaidev Srinivas Tantry, Laura Marie Patrick
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Patent number: 8808736Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.Type: GrantFiled: September 23, 2013Date of Patent: August 19, 2014Assignee: Zx Pharma, LLCInventors: Syed Shah, Daniel Hassan, Fred Hassan
-
Patent number: 8795721Abstract: A device for delivering a substance in situ in a body comprising at least one permeable expandable container having a first dimension and a second dimension and having contained therein the substance to be delivered; and at least one expandable particle comprising a swellable material contained within the container and capable of expanding when contacted with a fluid; whereby when the device is positioned in situ, bodily fluid permeates the container causing the at least one expandable particle contained therein to swell and the container to expand from the first dimension to the second dimension so that the device remains in situ for a period of time sufficient to achieve the desired delivery of the substance is provided.Type: GrantFiled: December 18, 2007Date of Patent: August 5, 2014Assignee: Eatlittle Inc.Inventors: Martin Pavlov Mintchev, Orly Yadid-Pecht, Michel Fattouche
-
Patent number: 8770201Abstract: Condoms having an elastomeric layer and coating containing an anhydrous warming lubricant and at least one or more ingredients dispersed therein, the coating being disposed on one or both surfaces are provided. The ingredients disposed on the elastomeric layer can be solid particles or encapsulated ingredients that are insoluble in the anhydrous warming lubricant and soluble in water. Methods of producing and using these condoms are also provided.Type: GrantFiled: October 23, 2008Date of Patent: July 8, 2014Assignee: GlycoBioSciences Inc.Inventors: Michael S. Zedalis, Beng Sim Chuah, David M. Lucas, Angela M. Shiokawa, Jose R. Siqueira, Dave Narasimhan
-
Patent number: 8758813Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.Type: GrantFiled: April 25, 2013Date of Patent: June 24, 2014Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander M. Klibanov
-
Patent number: 8747900Abstract: The invention relates to a pharmaceutical composition comprising cefuroximaxetil and at least one carrageenan selected from the group consisting of ?-carrageenan, ?-carrageenan and -carrageenan. The invention furthermore relates to pellets, to a multiparticulate, pharmaceutical dosage form and to a novel crystalline modification of cefuroximaxetil.Type: GrantFiled: April 25, 2006Date of Patent: June 10, 2014Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Andreas Fischer
-
Patent number: 8741343Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: December 2, 2010Date of Patent: June 3, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 8722650Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.Type: GrantFiled: August 23, 2010Date of Patent: May 13, 2014Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
-
Patent number: 8722083Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.Type: GrantFiled: June 25, 2012Date of Patent: May 13, 2014Assignee: Mylan, Inc.Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
-
Publication number: 20140127291Abstract: Disclosed herein is an extended release liquid pharmaceutical composition comprising extended release particles dispersed in a liquid medium. The extended release particles comprise acetaminophen dispersed or encapsulated in a water insoluble polymer and/or wax to provide an extended release dosage form of acetaminophen. The liquid medium comprises water, an active pharmaceutical ingredient in immediate release form and, optionally, excipients. The composition is storage stable for at least 6 months at 40° C. and 75% relative humidity.Type: ApplicationFiled: January 25, 2012Publication date: May 8, 2014Applicant: MAYNE PHARMA INTERNATIONAL PTY LTDInventor: Angelo Mario Morella
-
Publication number: 20140112985Abstract: This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.Type: ApplicationFiled: October 22, 2012Publication date: April 24, 2014Applicant: POLONEZ THERAPEUTICS LLCInventors: Wieslaw J. Bochenek, Michael L. Corrado
-
Patent number: 8701879Abstract: A capsule-in-capsule system comprising at least two segregated chemical reactants is described. An inner capsule contains one reactant and is itself contained, with a second chemical reactant, in an outer capsule. The inner capsule and its contents is fabricated first; then it is incorporated into the second reactant; and the combination of the second reactant and inner capsule is encapsulated in the outer capsule. The reactants may be hydrophobic or hydrophilic and present as fluids, solids or combinations of solid(s) and fluids(s). When subjected to suitably high pressure, the capsule wall materials will fracture or rupture, releasing and preferably mixing all encapsulates to enable their prompt reaction. The utility of the invention is illustrated by its application to development of a corrosion inhibiting passive film on magnesium auto body material and to the adhesive bonding of members where precise positioning is desired.Type: GrantFiled: January 14, 2010Date of Patent: April 22, 2014Assignee: GM Global Technology Operations LLCInventors: Tao Xie, Anil K. Sachdev
-
Patent number: 8685446Abstract: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is a dispersion of water, or aqueous extract or water dispersible material or water soluble material. The oil drops are encapsulated with a polymerisable material of natural origin. Such microcapsules are appropriated for spray-dry processes, to be used as dry powder, lyophilised, self-emulsifiable powder, gel, cream and any liquid form. The active compounds included in the microcapsules are beneficial to the health and other biological purposes.Type: GrantFiled: September 17, 2010Date of Patent: April 1, 2014Inventors: Victor Casana-Giner, Miguel Gimeno-Sierra, Barbara Gimeno-Sierra, Martha Moser
-
Patent number: 8685443Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.Type: GrantFiled: April 23, 2010Date of Patent: April 1, 2014Assignee: Alpharma Pharmaceuticals LLCInventor: Garth Boehm
-
Patent number: 8668932Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.Type: GrantFiled: March 18, 2011Date of Patent: March 11, 2014Assignee: Andrx Pharmaceuticals, LLCInventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
-
Patent number: 8663683Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: GrantFiled: August 27, 2012Date of Patent: March 4, 2014Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Patent number: 8663682Abstract: The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.Type: GrantFiled: January 22, 2004Date of Patent: March 4, 2014Assignee: EthypharmInventors: Philippe Chenevier, Dominique Marechal
-
Publication number: 20140050784Abstract: The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Elena KAGAN, Nitzan SHAHAR, Elina HARONSKY, Gregg R. DEROSA
-
Patent number: 8652516Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: GrantFiled: June 27, 2013Date of Patent: February 18, 2014Assignees: Cerovene, Inc., Galderma S.A.Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20140044780Abstract: Described herein is a pharmaceutical composition comprising levetiracetam as an active ingredient to provide prolonged release characteristic to allow once a day dosage regime. The innovative formulation comprises levetiracetam and a hydrophobic polymer with or without additional release rate modifier(s). The formulation may comprise other pharmaceutically acceptable excipients. This invention also describes the processes of preparing such dosage forms.Type: ApplicationFiled: August 5, 2013Publication date: February 13, 2014Inventors: I-Lan Tung Sue, Jung-Chung Lee
-
Publication number: 20140037723Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8642078Abstract: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.Type: GrantFiled: March 29, 2007Date of Patent: February 4, 2014Assignee: Lek Pharmaceuticals, D.D.Inventors: Igor Legen, Polonca Kuhar
-
Patent number: 8609136Abstract: Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more materials with an agent or an agent-releasing formulation to form an intergraded device; folding the intergrated delivery device to form a folded integrated delivery device; and at least partially enclosing the folded delivery device to a form suitable for oral delivery.Type: GrantFiled: March 13, 2013Date of Patent: December 17, 2013Assignee: Intec Pharma Ltd.Inventors: Moshe Tsabari, Avner Balshey, Erez Yofe, Michael Friedman
-
Patent number: 8592364Abstract: Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.Type: GrantFiled: February 10, 2011Date of Patent: November 26, 2013Assignee: Ecole Polytechnique Federale de Lausanne (“EPFL”)Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
-
Patent number: 8591920Abstract: Emulsions of lipophiles such as glycerol monostearate which are compatible with acrylic copolymer emulsions are made stable by using an emulsion stabilizer such as polysorbate 80 in an amount by weight between 1% and 5% of the lipophile and homogenizing the emulsion wherein the emulsion micelles are less than 50 microns. The ability to make a stable emulsion of a lipophile is important in the coating process as it enables preparation and shipment of the lipophilic emulsion to the coater rather than the preparation of a lipophilic emulsion at the time of the coating process which involves a heating and cooling process.Type: GrantFiled: October 28, 2005Date of Patent: November 26, 2013Assignee: Emerson Resources, Inc.Inventor: Charles Signorino
-
Patent number: 8580310Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.Type: GrantFiled: September 11, 2008Date of Patent: November 12, 2013Assignee: Purdue PharmaInventors: Thinnayam N. Krishnamurthy, Andrew Darke
-
Patent number: 8580301Abstract: The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.Type: GrantFiled: February 23, 2007Date of Patent: November 12, 2013Assignee: PEJO Iserlohn Heilmittel und Diaet GmbH & Co. KGInventors: Reiner Poestges, Bernd Schneider, Richard Ammer
-
Patent number: 8568774Abstract: A homogeneous gas-evolving composition is provided that includes an acid, a gas-evolving acid neutralizing agent, and at least one of an inorganic carbonate, inorganic bicarbonate, alkaline peroxide, or alkaline azide. A water-soluble desiccant is homogeneously intermixed with the acid and the gas-evolving acid neutralizing agent. The desiccant is present in an amount able to absorb ambient moisture equivalent to at least 0.01 total weight percent of the composition before gas evolution of more than 50% of the theoretical gas evolution available from the composition. To confer storage stability, the acid, the gas-evolving acid neutralizing agent, and water-soluble desiccant cumulatively have a water content of less than 1 total weight percent water. Through appropriate selection of a desiccant or inclusion of a surfactant foaming agent, the composition foams upon drenching with water. The composition is particularly well suited for consistent usage of glyphosate herbicide.Type: GrantFiled: February 8, 2010Date of Patent: October 29, 2013Assignee: The Andersons, Inc.Inventors: James R. Lynch, Timothy D. Birthisel, Jeffrey J. Fesko
-
Patent number: 8535799Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.Type: GrantFiled: February 27, 2007Date of Patent: September 17, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
-
Patent number: 8524829Abstract: The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.Type: GrantFiled: June 17, 2008Date of Patent: September 3, 2013Assignee: Brown University Research FoundationInventors: Edith Mathiowitz, Christopher Thanos, Zhi Liu
-
Patent number: 8506981Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: April 23, 2013Date of Patent: August 13, 2013Assignee: Synergy Biomedical LLPInventor: Mark D. Borden
-
Patent number: 8470364Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.Type: GrantFiled: December 17, 2010Date of Patent: June 25, 2013Assignee: Supernus Pharmaceuticals, Inc.Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
-
Patent number: 8465767Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.Type: GrantFiled: May 21, 2008Date of Patent: June 18, 2013Assignee: Takeda GmbHInventors: Rango Dietrich, Hartmut Ney
-
Patent number: 8460710Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: September 14, 2004Date of Patent: June 11, 2013Assignee: Shionogi, Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8449909Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: GrantFiled: June 25, 2010Date of Patent: May 28, 2013Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
-
Publication number: 20130078304Abstract: The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 28, 2011Publication date: March 28, 2013Applicant: TAIWAN BIOTECH CO., LTD.Inventors: HSIEN-JEN HSIEH, KUO-HUA YANG, CHIH-SHENG YANG, YU-CHENG WEI, CHUNG-HSUAN LU
-
Patent number: 8394405Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.Type: GrantFiled: December 17, 2010Date of Patent: March 12, 2013Assignee: Supernus Pharmaceuticals, Inc.Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
-
Patent number: 8394406Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.Type: GrantFiled: December 17, 2010Date of Patent: March 12, 2013Assignee: Supernus Pharmaceuticals, Inc.Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
-
Patent number: 8389004Abstract: The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention.Type: GrantFiled: October 7, 2009Date of Patent: March 5, 2013Assignee: University of PretoriaInventors: Janet Taylor, John Reginald Nuttall Taylor
-
Patent number: 8349353Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: June 29, 2009Date of Patent: January 8, 2013Assignees: Otonomy, Inc., The Regents of the University of CaliforniaInventors: Jay Lichter, Andrew M. Trammel, Jeffrey P. Harris, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary
-
Publication number: 20130004573Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.Type: ApplicationFiled: September 7, 2012Publication date: January 3, 2013Applicant: Alkermes Pharma Ireland LimitedInventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
-
Publication number: 20120321708Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Patent number: 8313776Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: July 20, 2004Date of Patent: November 20, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8313775Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: July 20, 2004Date of Patent: November 20, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Publication number: 20120276017Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.Type: ApplicationFiled: March 23, 2012Publication date: November 1, 2012Inventors: David Lickrish, Feng Zhang
-
Patent number: 8298576Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: GrantFiled: November 16, 2007Date of Patent: October 30, 2012Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Patent number: 8268804Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: September 3, 2010Date of Patent: September 18, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Patent number: 8252776Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: April 2, 2007Date of Patent: August 28, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Patent number: 8246996Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: August 20, 2004Date of Patent: August 21, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings